Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq analysis of PRCC-TFE3 dependent transcriptional programs and their modulation by MSC2530818 in HK-2 cells.

ABSTRACT: PRCC-TFE3 is an oncogenic chimeric transcription factor identified in TFE3-rearranged renal cell carcinoma. To characterize PRCC-TFE3–dependent transcriptional programs and their regulation by the Mediator kinase module, we performed RNA sequencing in a doxycycline-inducible PRCC-TFE3 expression system. HK-2 cells expressing HA-tagged PRCC-TFE3 under doxycycline control were cultured under four conditions defined by the presence or absence of doxycycline and the CDK8/19 inhibitor MSC2530818. RNA-seq was conducted to assess global gene expression changes associated with PRCC-TFE3 induction and CDK8/19 inhibition. These data provide a resource for analyzing PRCC-TFE3–driven transcriptional reprogramming and its modulation by the Cyclin C–CDK8/19 Mediator kinase module.

ORGANISM(S): Homo sapiens

PROVIDER: GSE316808 | GEO | 2026/03/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

HA-PRCC-TFE3 bound regions in HA-PRCC-TFE3 inducible HK-2 cells

Project description:PRCC-TFE3 is an oncogenic chimeric transcription factor derived from human TFE3-rearranged renal cell carcinoma. To analyze its genome-wide occupancy, we developed HA-tagged PRCC-TFE3-inducible HK-2 cell lines, which expresses HA-tagged TFE3 in a doxycycline-dependent manner. We determined the binding regions of HA-PRCC-TFE3 by ChIPSeq.

2025-01-22 | GSE281281 | GEO

Gene expression changes induced by HA-PRCC-TFE3 in HK-2 cells

Project description:PRCC-TFE3 is an oncogenic chimeric transcription factor identified in human TFE3-rearranged renal cell carcinoma. To analyze gene expression changes driven by PRCC-TFE3, we generated and utilized an HA-tagged PRCC-TFE3-inducible HK-2 cell line, which expresses HA-tagged PRCC-TFE3 in a doxycycline-dependent manner. Cells were cultured with or without doxycycline, and comprehensive gene expression analysis was conducted using RNA-seq.

2025-01-07 | GSE278984 | GEO

Genome-wide CRISPR sgRNA loss-of-function screening in PRCC-TFE3 inducible HK-2 cells

Project description:PRCC-TFE3 is an oncogenic chimeric transcription factor that drives TFE3-rearranged renal cell carcinoma. Although PRCC-TFE3 can trigger either oncogene-induced senescence (OIS) or tumor progression depending on the cellular context, both phenotypes are fundamentally dependent on its transcriptional function. This study aims to identify genetic factors essential for the transcriptional activity and functional output of PRCC-TFE3. Using a doxycycline (Dox)-inducible PRCC-TFE3 HK-2 cell model where the fusion protein induces robust OIS, we performed a genome-wide CRISPR/Cas9 knockout screen. By identifying genes whose loss alleviates this OIS phenotype, we sought to uncover key regulators required for PRCC-TFE3-mediated transcriptional programs.

2026-03-18 | GSE316868 | GEO

Gene expression changes induced by HA-PRCC-TFE3 in HEK293 cells

Project description:PRCC-TFE3 is an oncogenic chimeric transcription factor identified in human TFE3-rearranged renal cell carcinoma. To analyze gene expression changes driven by PRCC-TFE3, we generated and utilized an HA-tagged PRCC-TFE3-inducible HEK293 cell line, which expresses HA-tagged PRCC-TFE3 in a doxycycline-dependent manner. Cells were cultured with or without doxycycline, and comprehensive gene expression analysis was conducted using Affymetrix arrays .

2025-01-07 | GSE281146 | GEO

HA-PRCC-TFE3 bound regions in HA-PRCC-TFE3 inducible HK-2 cells

Project description:HA-PRCC-TFE3 bound regions in HA-PRCC-TFE3 inducible HK-2 cells

| PRJNA1183309 | ENA

PRCC-TFE3 Function and the Role of HIF1α and HIF2α in TFE3-Rearranged Renal Cell Carcinoma Development

Project description:PRCC-TFE3 is an oncogenic chimeric transcription factor identified in human TFE3-rearranged renal cell carcinoma. To investigate the function of PRCC-TFE3 in vivo, we generated PRCC-TFE3 knock-in (KI) mice by inserting a loxP-STOP-loxP-PRCC-TFE3 cassette into the Rosa26 locus. When PRCC-TFE3 KI mice were crossed with Cadherin 16-Cre transgenic mice (KSP-Cre), the resulting mice developed TFE3-RCC in the kidney. Our findings revealed that hypoxia-inducible factors HIF1α and HIF2α are directly upregulated by PRCC-TFE3. To clarify the roles of HIF1α and HIF2α in TFE3-RCC development, we further crossed PRCC-TFE3 KI mice with HIF1α flox and/or HIF2α flox mice.

2025-01-07 | GSE283743 | GEO

Mediator Kinase Complexes Regulates ATOH1-Dependent Intestinal Differentiation

Project description:Cyclin Dependent Kinases CDK8 and CDK19 (Mediator kinase) are regulatory components of the Mediator complex, a highly conserved complex that fine tunes transcriptional output. While Mediator kinase has been implicated in the transcriptional control of key pathways necessary for development and growth, its function in vivo has not been well described. Herein, we report the consequences of complete ablation of both Cdk8/19 on tissue homeostasis. We show that intestinal epithelial specific deletion of Mediator kinase leads to a distinct defect in secretory progenitor differentiation with broad loss of the intestinal secretory cell types. Using a phospho-proteogenomic approach, we show that the Cdk8/19 kinase module interacts with and phosphorylates components of the chromatin remodeling complex Swi/Snf in intestinal epithelial cells. Genomic localisation of Swi/Snf and Mediator shows Cdk8/19-dependent genomic binding at distinct super-enhancer loci within key lineage specification genes, including the master regulator of secretory differentiation ATOH1. Using CRISPRi/CRISPRa, we identify a distinct Mediator- Swi/Snf bound enhancer element that is necessary and sufficient for ATOH1 expression in a Mediator-kinase dependent manner. As such, these studies uncover a newly described transcriptional mechanism of ATOH1-dependent intestinal cell specification that is dependent on the coordinated interaction of the chromatin remodeling complex Swi/Snf and Mediator complex.

2023-03-10 | PXD030212 | Pride

Colorectal Cancer Organoid Proteomics

Project description:Cyclin Dependent Kinases CDK8 and CDK19 (Mediator kinase) are regulatory components of the Mediator complex, a highly conserved complex that fine tunes transcriptional output. While Mediator kinase has been implicated in the transcriptional control of key pathways necessary for development and growth, its function in vivo has not been well described. Herein, we report the consequences of complete ablation of both Cdk8/19 on tissue homeostasis. We show that intestinal epithelial specific deletion of Mediator kinase leads to a distinct defect in secretory progenitor differentiation with broad loss of the intestinal secretory cell types. Using a phospho-proteogenomic approach, we show that the Cdk8/19 kinase module interacts with and phosphorylates components of the chromatin remodeling complex Swi/Snf in intestinal epithelial cells. Genomic localisation of Swi/Snf and Mediator shows Cdk8/19-dependent genomic binding at distinct super-enhancer loci within key lineage specification genes, including the master regulator of secretory differentiation ATOH1. Using CRISPRi/CRISPRa, we identify a distinct Mediator-Swi/Snf bound enhancer element that is necessary and sufficient for ATOH1 expression in a Mediator-kinase dependent manner. As such, these studies uncover a newly described transcriptional mechanism of ATOH1-dependent intestinal cell specification that is dependent on the coordinated interaction of the chromatin remodeling complex Swi/Snf and Mediator complex.

2023-03-11 | PXD030256 | Pride

Downregulation of MED12 via siRNA in SPHEROIDS derived from prostate cancer cell lines (3’ tag DGE)

Project description:The Mediator complex is a multi-subunit protein that modulates gene expression on a genome-wide scale. MED12 and cyclin-dependent kinase 8 (CDK8) or its paralog CDK19 are components of its kinase module that regulate the proliferation of prostate cancer cells. In this study, we investigated how MED12 and CDK8/19 influence cancer-driven processes in prostate cancer cell lines, focusing on AR activity and enzalutamide resistance.

2024-09-26 | GSE269073 | GEO

Downregulation of MED12 via siRNA in prostate cancer cell lines (3’ tag DGE)

2024-09-26 | GSE269072 | GEO